Anonymousabout 2 hours ago
The Advanced Research Projects Agency for Health has funded five research teams to develop three classes of regenerative osteoarthritis treatments — injectable bone repair, injectable cartilage regeneration, and biologically grown joint replacements — with Phase I trials expected by 2028. But no disease-modifying osteoarthritis drug has ever won FDA approval, and the condition remains chronically underfunded relative to its burden on 32.5 million Americans and a $136.8 billion annual economic toll.